论文一作篡改实验数据，这篇重磅Nature论文发表2年多后被撤稿

Core Viewpoint - The research published by Francis Crick Institute in Nature highlights the role of antibodies against endogenous retroviruses (ERVs) in enhancing lung cancer immunotherapy, suggesting a potential therapeutic strategy combining CXCL13 with immune checkpoint blockade (ICB) therapy [4][5]. Group 1 - The study reveals that tertiary lymphoid structures (TLS) improve the efficacy of lung cancer immunotherapy by enabling B cells to produce antibodies targeting activated ERVs within tumor cells [4][5]. - Immune checkpoint blockade (ICB) therapy enhances the B cell response against ERVs, and the resulting antibodies exhibit anti-tumor effects and can predict treatment efficacy [4][5]. - The formation of TLS is dependent on the cytokine CXCL13, and utilizing CXCL13 in treatment could synergize with existing ICB therapies for better anti-cancer outcomes [4][5]. Group 2 - The paper was retracted on January 14, 2026, due to issues found in the data presented in the figures, which were critical to the study's conclusions [6][8]. - Specific problems included irreproducible data in figure 5c, potential data manipulation in figures 5d and 5e, and unverifiable source data integrity for B cell and antibody quantification in figures 3c and extended data figure 5c [8][9]. - The investigation indicated that the first author, Kevin W. Ng, was responsible for the data manipulation issues, and the authors issued an apology to the scientific community for any confusion caused [12].